Side-by-side financials for ALZN and JNJ. Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ALZN | JNJ |
|---|---|---|
| Market cap | - | $574.10 B |
| US-listed rank | - | #20 |
| Revenue (latest FY) | - | $94.19B |
| Net income (latest FY) | -$4.51M | $26.80B |
| Net margin | - | 28.5% |
| P/E (trailing FY) | - | 21.4 |
| SEC filings | 374 | 984 |
Full pages: Alzamend Neuro, Inc. and JOHNSON & JOHNSON, or browse the full rankings.